| Co.don–SEVERAL: investment, 201510–201511 capital increase €5m with 2.5m new shares at €2/share w existing + new investors |
2015-10-30 |
| GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015 |
2015-10-29 |
| Agena Bioscience–Diatech: mass spec-based MDx, 201510– collab developm MassARRAY genomic CDx tests for cancer therapy w Diatech Pharmacogenetics Srl |
2015-10-27 |
| Biofrontera–SEVERAL: investment, 201510–201511 capital increase €3.64m net €3.1m with 1.92m new shares at €2/share |
2015-10-27 |
| Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management |
2015-10-21 |
| Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
| Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
| Pronutria–Bertarelli Group: investment, 201510 investment €na by Gurnet Point Capital completing Pronutria’s Series C financing |
2015-10-15 |
| Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round |
2015-10-09 |
| Marinomed–Austria (govt): investment, 201510 aws Mittelstandsfonds aquires share in Marinomed |
2015-10-06 |
| Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech |
2015-10-01 |
| JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate |
2015-09-28 |
| Beijing Clear Biotech–Curetis: Unyvero platform, 201509– distribution excl in Greater China of system + 2 cartridges by BCB |
2015-09-25 |
| Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform |
2015-09-17 |
| Evolva–SEVERAL: investment, 201509 rights offering CHF57.4m |
2015-09-16 |
| Nestlé–Lipid Therapeutics: gastrointestinal drug, 201609– license excl to develop + market LT-02 ww excl Europe + Australia to Nestlé Health Science |
2015-09-16 |
| Lophius–SEVERAL: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF |
2015-09-10 |
| Lophius–High-Tech Gründerfonds: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF |
2015-09-09 |
| Baxalta–Novimmune: therapeutic antibodies, 201509– collab r+d €na bispecific antibodies for hemophilia A |
2015-09-02 |
| Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis |
2015-09-01 |
| Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management |
2015-09-01 |
| Hisun Pharmaceutical–IMD Natural Solutions: drug discovery, 201508– collab using IMD natural product lead discovery platform incl €4m investment |
2015-08-31 |
| IMD Natural Solutions–Hisun Pharmaceutical: investment, 201508 equity investment €4m as part of collab with Zhejiang Hisun Pharmaceutical Co Ltd |
2015-08-31 |
| Immatics–Texas (govt): grant, 201508 launch of Immatics US Inc supported by $19.7m grant from CPRIT |
2015-08-26 |
| Immatics–Univ Texas: cell therapy, 201508– collab launch joint venture Immatics US Inc with MD Anderson to advance adoptive cellular therapies |
2015-08-26 |
| Merus–Novartis: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round incl existing investor Novartis Venture Fund |
2015-08-26 |
| Nomad Bioscience–Denka: investment, 201508–201708 acquisition up to €75m of 51% share in Icon Genetics GmbH + after 2y acquiring rest by Denka |
2015-08-07 |
| Mereo BioPharma–Novartis: investment, 201507 Novartis receives equity stake in consideration for acquisition of 3 programmes from Novartis by Mereo |
2015-07-29 |
| Protembis–SEVERAL: investment, 201507 seed financing round 7-digit € incl Innovationsstarter Fonds + Geratherm + angel investors |
2015-07-28 |
| Poxel–MacDougall Biomedical Communications: public relations, 201507 service existent IR + PR in EU + US |
2015-07-24 |
| Memo Therapeutics–SEVERAL: investment, 201507 financing round Series A CHF2.3m from Swiss investors incl EVA Basel + Redalpine + Zürcher Kantonalbank |
2015-07-22 |
| Allergan–Molecular Partners: ophthalmics, 201507– collab expansion of DARPin alliance in ophthalmology |
2015-07-21 |
| Accurate Mass Scientific–CovalX: mass spectrometry, 201507– collab AMS new Australian distributor of CovalX High-Mass systems + CRO analytics services |
2015-07-15 |
| AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock |
2015-07-14 |
| InSphero–HP Wild Holding: investment, 201507 Series C financing CHF20m from HP Wild Holding AG |
2015-07-08 |
| Actelion–Max Planck: vaccine technology, 201506 license excl synthetic carbohydrate vaccines for new Vaxillion joint venture from + with Max Planck |
2015-06-26 |
| Vaxxilon–Actelion: investment, 201506 founding w Max Planck + Actelion as majority owner w committed funding of €30m over 4y in tranches |
2015-06-26 |
| ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws |
2015-06-23 |
| ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
| ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
| Juno Therapeutics–Editas Medicine: cancer immunotherapy, 201505– strategic alliance to develop CAR-T + engineered TCR therapies |
2015-05-27 |
| Merus–EU (govt): grant, 201505– Eureka Eurostars grant totalling €2.1m for Merus + Selexis to develop bispecific antibody drugs for colorectal cancer |
2015-05-20 |
| Merus–Selexis: antibody cancer drug, 201505– collab combining Oligoclonics + SUREtechnology to develop bispecific antibody drugs for colorectal cancer |
2015-05-20 |
| Selexis–EU (govt): grant, 201505– Eureka Eurostars grant totalling €2.1m for Merus + Selexis to develop bispecific colorectal cancer antibody drugs |
2015-05-20 |
| Curasan–SEVERAL: investment, 201505 capital increase €1m with 730k new shares at €1.4/share |
2015-05-19 |
| OctreoPharm–Ipsen: investment, 201505 acquisition 100% by Ipsen for up to €50m incl an upfront payment + milestones |
2015-05-19 |
| Novartis–BioQuiddity: pharmaceutical, 201505– excl license + supply for ready-to-use ropivacaine + proponal infusions to Sandoz in US |
2015-05-13 |
| Cytos Biotechnology–SEVERAL: investment, 201505 conversion of all outstanding convertible bonds into 77.49m new shares making Cytos debt free |
2015-05-08 |
| Arcus Biosciences–Novartis: investment, 201505 financing round Series A totalling $49.7m incl co-investor Novartis |
2015-05-01 |
| Arcus Biosciences–SEVERAL: investment, 201505 financing round Series A $49.7m incl F&F + Column Group + Foresite Capital + Novartis + Celgene |
2015-05-01 |
| Auris Medical–SEVERAL: investment, 201505 public offering $25m with 5.275m common shares at $4.75/share |
2015-05-01 |
| Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology |
2015-05-01 |
| Strüngmann Group–Formycon: biosimilar, 201505– license ww excl to Eylea biosimilar FYB203 to Santo Holding GmbH |
2015-05-01 |
| Formycon–SEVERAL: investment, 201504 capital increase €11.1m with 435.9k new shares at €25.5/share to instituional investors + family offices |
2015-04-16 |
| Menarini–4SC: resminostat, 201504– collab license + developm €95m upfront + milestones + royalties for Asia-Pacific excl JP Menarini Asia-Pacific |
2015-04-14 |
| Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors |
2015-04-08 |
| Caribou Biosciences–SEVERAL: investment, 201504 financing round Series A $11m incl Fidelity Biosciences + Novartis + Mission Bay Capital et al |
2015-04-02 |
| vivoPharm–Protea Biosciences: investment, 201503–201601 acquisition $12m in cash + shares subject to raising necessary financing NOT REALISED |
2015-03-31 |
| Sumitomo–Evolva: agri bioactives, 201503– collab excl developm + commercialisation of ingredient class by Valent BioSciences |
2015-03-26 |
| Mologen–SEVERAL: investment, 201503–201504 capital increase €28.3m with 5.66m new shares at €5/share |
2015-03-24 |
| Sanofi–Evotec: drug discovery, 201503– collab strategic alliance 5 years minimum €250m with €40m upfront |
2015-03-20 |
| AdnaGen–Qiagen: investment, 201503 acquisition of assets by Qiagen via newly established Qiagen Hannover GmbH |
2015-03-16 |
| Boehringer–Artes Biotechnology: vaccine technology, 201503– collab using Hansenula expression system + Metavax platform for animal vaccine development |
2015-03-16 |
| Tokai Pharmaceuticals–Qiagen: molecular companion diagnostics, 201503– collab developm + commercialistion of CTC-based CDx for galeterone |
2015-03-16 |
| Addex–SEVERAL: investment, 201503 private placement CHF2.8m with 1.53m new shares led by Herculis Partners SA |
2015-03-09 |
| CureVac–Gates Foundation: investment, 201503 equity investment €46m by Gates Foundation |
2015-03-05 |
| CureVac–Hopp Group: investment, 201503 equity investment €21m by dievini Hopp BioTech Holding |
2015-03-05 |
| CureVac–SEVERAL: investment, 201503 private placement €67m from Gates Foundation + dievini Hopp BioTech |
2015-03-05 |
| Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital |
2015-03-04 |
| Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne |
2015-03-04 |
| Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund |
2015-03-04 |
| Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures |
2015-03-04 |
| Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One |
2015-03-04 |
| OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit |
2015-03-03 |
| Pfizer–Genedata: bioinformatics, 201503– supply license to Genedata Biologics enterprise platform for Pfizer RnD Sites in US + Europe |
2015-03-03 |
| APR Applied Pharma Research–HBM: investment, 201503 acquisition of €na minority stake by HBM Partners |
2015-03-01 |
| Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m |
2015-03-01 |
| Canbex Therapeutics–Ipsen: investment, 201502 Ipsen pays €6m upfront for option to acquire Canbex upon Ph2a completion of VSN16R in MS spasticity |
2015-02-24 |
| Prexton Therapeutics–Merck (DE): investment, 201502 financing round Series A totalling €8.7m incl returning founding + co-investor MS Ventures |
2015-02-24 |
| Prexton Therapeutics–SEVERAL: investment, 201502 financing round Series A €8.7m co-led by Sunstone Capital + Ysios Capital plus MS Ventures |
2015-02-24 |
| Prexton Therapeutics–Sunstone Capital: investment, 201502 financing round Series A totalling €8.7m incl co-lead investor Sunstone Capital |
2015-02-24 |
| Prexton Therapeutics–Ysios Capital: investment, 201502 financing round Series A totalling €8.7m incl co-lead investor Ysios Capital |
2015-02-24 |
| NBE Therapeutics–Boehringer: investment, 201502 financing round Series A totalling CHF3m led by Boehringer Ingelheim Venture Fund |
2015-02-20 |
| NBE Therapeutics–SEVERAL: investment, 201502 financing round Series A CHF3m led by Boehringer Ingelheim Venture Fund |
2015-02-20 |
| Argenx–Lonza: gene expression system, 201502– license multi-product for GS Xceed System for production of therapeutic antibodies |
2015-02-18 |
| Boehringer–Genedata: bioinformatics, 201502– supply license to Genedata Biologics platform for BI RnD Sites in US + Europe |
2015-02-18 |
| Immunservice–High-Tech Gründerfonds: investment, 201502 financing round Series C incl existing investor HTGF |
2015-02-18 |
| Immunservice–SEVERAL: investment, 201502 financing round Series C from Michael Otto + Helmut Ponath + Hubertus-Wald-Stiftung + HTGF + Hartwig Huland |
2015-02-18 |
| AC Immune–Michael J Fox Foundation: grant, 201502 research grant €na for developm of PET tracers for alpha-synuclein protein in Parkinson diagnosis |
2015-02-12 |
| Exquiron Biotech–SAMDI Tech: drug discovery services, 201502– collab mutually co-promotion of respective services in Europe + North America |
2015-02-08 |
| R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m |
2015-02-01 |
| ASPEC Technologies–CovalX: mass spectrometry, 201501 collab existent ASPEC is distributor of CovalX High-Mass systems in China |
2015-01-15 |
| Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion r+d small-molecule KRAS inhibitors for cancer |
2015-01-13 |
| Cortendo–SEVERAL: investment, 201501 private placement $27.5m (SEK221m) incl RA Capital + NEA + Broadfin Capital + HealthCap |
2015-01-13 |
| GenePOC–Debiopharm: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital |
2015-01-13 |
| GenePOC–SEVERAL: investment, 201501 financing round led by Debiopharm Diagnostics + Emerillon Capital |
2015-01-13 |
| Addex–United States (govt): ADX71441, 201501– collab NIAAA to evaluate ADX71441 in preclinical models of alcohol use disorder |
2015-01-07 |
| OnCore BioPharma–Cytos Biotechnology: VLP technology, 201501– license to OnCore excl for use of VLP platform in treatm + prevention of HBV infections |
2015-01-06 |
| Provendis–TVM: venture capital, 201501– collab support in project evaluation + financing by TVM Capital Life Science for projects of Provendis |
2015-01-06 |
| Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF |
2015-01-01 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 30 31 32 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
